

Nancy Y Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8638669/publications.pdf>

Version: 2024-02-01

323
papers

27,255
citations

9775

73
h-index

7152

153
g-index

333
all docs

333
docs citations

333
times ranked

24356
citing authors

#	ARTICLE	IF	CITATIONS
1	Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2004, 350, 1937-1944.	13.9	2,756
2	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
3	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 567-610.	2.4	1,738
4	Chromosomal instability drives metastasis through a cytosolic DNA response. <i>Nature</i> , 2018, 553, 467-472.	13.7	1,002
5	Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 12-22.	0.4	924
6	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 1104-1139.	2.4	717
7	CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. <i>Radiotherapy and Oncology</i> , 2003, 69, 227-236.	0.3	611
8	Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225. <i>Journal of Clinical Oncology</i> , 2009, 27, 3684-3690.	0.8	607
9	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. <i>Lancet Oncology</i> , The, 2016, 17, 440-451.	5.1	607
10	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
11	Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. <i>Lancet Oncology</i> , The, 2012, 13, 172-180.	5.1	291
12	Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 450-462.	5.1	287
13	Intensity-modulated radiation therapy for head-and-neck cancer: The UCSF experience focusing on target volume delineation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 49-60.	0.4	272
14	Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: The Memorial Sloan-Kettering Cancer Center experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 363-373.	0.4	272
15	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-37.	0.8	239
16	Salvage Re-Irradiation for Recurrent Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 731-740.	0.4	235
17	Fluorine-18-Labeled Fluoromisonidazole Positron Emission and Computed Tomography-Guided Intensity-Modulated Radiotherapy for Head and Neck Cancer: A Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 2-13.	0.4	220
18	Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 630-637.	0.4	214

#	ARTICLE	IF	CITATIONS
19	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2018, 126, 25-36.	0.3	214
20	Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting—the MSKCC experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 691-702.	0.4	213
21	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 729.	5.8	212
22	Reproducibility of Intratumor Distribution of 18F-Fluoromisonidazole in Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 235-242.	0.4	209
23	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. <i>JAMA Oncology</i> , 2017, 3, 244.	3.4	191
24	Long-term regional control and survival in patients with low-risk, early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation. <i>Cancer</i> , 2013, 119, 1168-1176.	2.0	189
25	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 840-859.	0.8	178
26	Intensity-modulated radiation therapy in head and neck cancers: An update. <i>Head and Neck</i> , 2007, 29, 387-400.	0.9	175
27	PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2009, 50, 745-88S.	2.8	172
28	The Influence of Changes in Tumor Hypoxia on Dose-Painting Treatment Plans Based on 18F-FMISO Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1219-1228.	0.4	168
29	Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 291-298.	0.4	168
30	¹⁸ F-FDG PET/CT Metabolic Tumor Volume and Total Lesion Glycolysis Predict Outcome in Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1506-1513.	2.8	161
31	Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. <i>Radiotherapy and Oncology</i> , 2016, 118, 286-292.	0.3	160
32	The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience. <i>Oral Oncology</i> , 2017, 64, 44-51.	0.8	159
33	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 618-627.	0.4	156
34	Decision making in the management of recurrent head and neck cancer. <i>Head and Neck</i> , 2014, 36, 144-151.	0.9	153
35	The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. <i>Nature Communications</i> , 2018, 9, 3292.	5.8	153
36	An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 2208-2215.	3.2	149

#	ARTICLE	IF	CITATIONS
37	A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 966-974.	0.4	146
38	Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. <i>JAMA Oncology</i> , 2017, 3, 1487.	3.4	146
39	Results of Surgical Salvage After Failure of Definitive Radiation Therapy for Early-Stage Squamous Cell Carcinoma of the Glottic Larynx. <i>JAMA Otolaryngology</i> , 2006, 132, 59.	1.5	139
40	Recurrence in Region of Spared Parotid Gland After Definitive Intensity-Modulated Radiotherapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 660-665.	0.4	139
41	Concurrent Cisplatin and Radiation Versus Cetuximab and Radiation for Locally Advanced Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 915-922.	0.4	137
42	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Predictor of Outcome in Head-and-Neck Squamous Cell Carcinoma Patients With Nodal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1837-1844.	0.4	137
43	Carcinomas of the Paranasal Sinuses and Nasal Cavity Treated With Radiotherapy at a Single Institution Over Five Decades: Are We Making Improvement?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 141-147.	0.4	132
44	Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 386-395.	0.4	132
45	Efficacy of Skin-Directed Therapy for Cutaneous Metastases From Advanced Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3144-3155.	0.8	131
46	Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma. <i>Cancer</i> , 2008, 113, 497-507.	2.0	130
47	Development and Validation of a Standardized Method for Contouring the Brachial Plexus: Preliminary Dosimetric Analysis Among Patients Treated With IMRT for Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1362-1367.	0.4	129
48	Role of External Beam Radiotherapy in Patients With Advanced or Recurrent Nonanaplastic Thyroid Cancer: Memorial Sloan-Kettering Cancer Center Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 795-801.	0.4	127
49	Nasopharyngeal Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 547-561.	0.6	127
50	Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Locoregionally Advanced Laryngeal and Hypopharyngeal Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 459-468.	0.4	126
51	Prospective Trial Incorporating Pre-/Mid-Treatment [18F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 101-108.	0.4	126
52	Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 110, 390-397.	0.3	126
53	Outcomes and Prognostic Variables in Adenoid Cystic Carcinoma of the Head and Neck: A Recent Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1365-1372.	0.4	122
54	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 9-17.	0.4	121

#	ARTICLE	IF	CITATIONS
55	Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: What is the role of elective neck irradiation?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 988-994.	0.4	116
56	Correlation of Osteoradionecrosis and Dental Events With Dosimetric Parameters in Intensity-Modulated Radiation Therapy for Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e207-e213.	0.4	114
57	Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States. <i>JAMA Oncology</i> , 2016, 2, 1617.	3.4	114
58	Intensity-Modulated Radiotherapy in Postoperative Treatment of Oral Cavity Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1096-1103.	0.4	109
59	A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. <i>Cancer</i> , 2015, 121, 294-301.	2.0	109
60	Intensity-Modulated Radiation Therapy for Head and Neck Carcinoma. <i>Oncologist</i> , 2007, 12, 555-564.	1.9	106
61	Proton therapy for head and neck cancer: expanding the therapeutic window. <i>Lancet Oncology</i> , The, 2017, 18, e254-e265.	5.1	106
62	Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 586-594.	0.4	105
63	Noninvasive Assessment of Tumor Microenvironment Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging and 18F-Fluoromisonidazole Positron Emission Tomography Imaging in Neck Nodal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1403-1410.	0.4	102
64	A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 595-605.	0.4	101
65	Reirradiation of Locally Recurrent Nasopharynx Cancer With External Beam Radiotherapy With or Without Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 130-137.	0.4	100
66	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 742-751.	3.0	98
67	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 567-580.	0.4	96
68	Proton Therapy for Head and Neck Cancers. <i>Seminars in Radiation Oncology</i> , 2018, 28, 53-63.	1.0	89
69	Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. <i>Radiotherapy and Oncology</i> , 2011, 101, 425-430.	0.3	88
70	Unresectable Carcinoma of the Paranasal Sinuses: Outcomes and Toxicities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 763-769.	0.4	82
71	Detailed Analysis of Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic Factors Between Surgically Treated HPV-Positive and Negative Oropharyngeal Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 4411-4421.	0.7	80
72	Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 158-168.	0.4	78

#	ARTICLE	IF	CITATIONS
73	Hypofractionated Dose-Painting Intensity Modulated Radiation Therapy With Chemotherapy for Nasopharyngeal Carcinoma: A Prospective Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 148-153.	0.4	78
74	External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. <i>Head and Neck</i> , 2016, 38, 493-498.	0.9	76
75	A nomogram to predict loco-regional control after re-irradiation for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014, 111, 382-387.	0.3	75
76	Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1419-1426.	0.4	74
77	Practical Considerations in the Re-Irradiation of Recurrent and Second Primary Head-and-Neck Cancer: Who, Why, How, and How Much?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1211-1219.	0.4	74
78	Patterns of recurrence in oral tongue cancer with perineural invasion. <i>Head and Neck</i> , 2018, 40, 1287-1295.	0.9	73
79	Intensity-Modulated Radiotherapy for Head and Neck Cancer of Unknown Primary: Toxicity and Preliminary Efficacy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1100-1107.	0.4	72
80	Geometric factors influencing dosimetric sparing of the parotid glands using IMRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 296-304.	0.4	71
81	A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. <i>Cancer</i> , 2012, 118, 5008-5014.	2.0	71
82	Tumor Immunity and Immunotherapy for HPV-Related Cancers. <i>Cancer Discovery</i> , 2021, 11, 1896-1912.	7.7	71
83	Merkel Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 322-332.	2.3	70
84	Intensity-Modulated Radiation Therapy in Oropharyngeal Carcinoma: Effect of Tumor Volume on Clinical Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1851-1857.	0.4	70
85	Taselisib (GDC-0032), a Potent $\hat{2}$ -Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PI3CA Alterations. <i>Clinical Cancer Research</i> , 2016, 22, 2009-2019.	3.2	70
86	Parotid gland fat related Magnetic Resonance image biomarkers improve prediction of late radiation-induced xerostomia. <i>Radiotherapy and Oncology</i> , 2018, 128, 459-466.	0.3	69
87	Pharmacokinetic Analysis of Hypoxia ^{18}F -Fluoromisonidazole Dynamic PET in Head and Neck Cancer. <i>Journal of Nuclear Medicine</i> , 2010, 51, 37-45.	2.8	68
88	Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 606-617.	0.4	68
89	Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. <i>Oral Oncology</i> , 2015, 51, 957-962.	0.8	67
90	Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. <i>Head and Neck</i> , 2016, 38, 1310-1317.	0.9	65

#	ARTICLE	IF	CITATIONS
91	Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. <i>Cancer</i> , 2020, 126, 3900-3906.	2.0	62
92	Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. <i>Physics in Medicine and Biology</i> , 2009, 54, 3083-3099.	1.6	61
93	Intensity-modulated radiation therapy for nasopharyngeal carcinoma: a review. <i>Journal of Radiation Oncology</i> , 2012, 1, 129-146.	0.7	59
94	Technology for Innovation in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 485-492.	0.4	58
95	Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 27-31.	0.6	58
96	Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. <i>Scientific Reports</i> , 2016, 6, 21371.	1.6	58
97	Head-and-Neck Target Delineation Among Radiation Oncology Residents After a Teaching Intervention: A Prospective, Blinded Pilot Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 416-423.	0.4	57
98	Patterns of regional and distant metastasis in esthesioneuroblastoma. <i>Laryngoscope</i> , 2016, 126, 1556-1561.	1.1	57
99	Human papillomavirus 16 promotes microhomology-mediated end-joining. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 21573-21579.	3.3	57
100	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 655-663.	3.0	56
101	Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy. <i>Cancer</i> , 2012, 118, 6072-6078.	2.0	55
102	External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. <i>Journal of Surgical Oncology</i> , 2014, 110, 375-382.	0.8	55
103	Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features. <i>Radiotherapy and Oncology</i> , 2018, 127, 36-42.	0.3	55
104	Intensity-Modulated Radiation Therapy in Head and Neck Cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 415-423.	0.6	54
105	Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis. <i>Cancer</i> , 2015, 121, 2083-2089.	2.0	54
106	Choosing an Intensity-Modulated Radiation Therapy Technique in the Treatment of Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1299-1309.	0.4	53
107	The role of external beam radiotherapy in the treatment of papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2006, 13, 971-977.	1.6	52
108	Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma. <i>Oral Oncology</i> , 2015, 51, 716-723.	0.8	52

#	ARTICLE	IF	CITATIONS
109	Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). <i>Oral Oncology</i> , 2014, 50, 947-955.	0.8	51
110	Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics. <i>Physics in Medicine and Biology</i> , 2017, 62, 5327-5343.	1.6	51
111	A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 564-570.	0.4	51
112	Intravoxel incoherent motion diffusion-weighted MRI during chemoradiation therapy to characterize and monitor treatment response in human papillomavirus head and neck squamous cell carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1013-1023.	1.9	50
113	An investigation of intensity-modulated radiation therapy versus conventional two-dimensional and 3D-conformal radiation therapy for early stage larynx cancer. <i>Radiation Oncology</i> , 2010, 5, 74.	1.2	49
114	Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. <i>Laryngoscope</i> , 2017, 127, 2265-2269.	1.1	49
115	Patient Reflections on Decision Making for Laryngeal Cancer Treatment. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 156, 299-304.	1.1	47
116	Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. <i>Journal of Clinical Oncology</i> , 2022, 40, 3858-3867.	0.8	47
117	Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: Technique, early outcomes, and toxicity. <i>Head and Neck</i> , 2008, 30, 925-932.	0.9	46
118	Proton Therapy for Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 28.	1.3	46
119	Dosimetric distribution to the tooth-bearing regions of the mandible following intensity-modulated radiation therapy for base of tongue cancer. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012, 114, e50-e54.	0.2	45
120	Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2016, 53, 67-73.	0.8	44
121	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. <i>JAMA Oncology</i> , 2018, 4, 1073.	3.4	44
122	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 682-695.	0.4	42
123	Texture analysis on parametric maps derived from dynamic contrast-enhanced magnetic resonance imaging in head and neck cancer. <i>World Journal of Radiology</i> , 2016, 8, 90.	0.5	42
124	Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature. <i>Head and Neck</i> , 2012, 34, 753-757.	0.9	41
125	JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer. <i>Future Oncology</i> , 2019, 15, 687-694.	1.1	41
126	Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 130-142.	0.8	40

#	ARTICLE	IF	CITATIONS
127	New Developments in Radiation Therapy for Head and Neck Cancer: Intensity-Modulated Radiation Therapy and Hypoxia Targeting. <i>Seminars in Oncology</i> , 2008, 35, 236-250.	0.8	39
128	Clinical outcomes, local regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. <i>Radiotherapy and Oncology</i> , 2020, 149, 205-211.	0.3	39
129	Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. <i>JAMA Oncology</i> , 2022, 8, 364.	3.4	39
130	Evaluation of Different Methods of 18F-FDG-PET Target Volume Delineation in the Radiotherapy of Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 439-445.	0.6	38
131	Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. <i>Radiotherapy and Oncology</i> , 2014, 111, 340-347.	0.3	38
132	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNP3-ALK rearrangement. <i>Human Pathology</i> , 2019, 88, 66-77.	1.1	38
133	Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. <i>Cancer</i> , 2020, 126, 444-452.	2.0	38
134	Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	3.0	38
135	Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy. <i>Journal of Skin Cancer</i> , 2014, 2014, 1-7.	0.5	37
136	Facility Volume and Survival in Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 408-417.	0.4	37
137	Dose-volume factors correlating with trismus following chemoradiation for head and neck cancer. <i>Acta Oncologica</i> , 2016, 55, 99-104.	0.8	36
138	Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3110-3116.	3.2	36
139	Phase II trial of bevacizumab+cetuximab+cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E566-70.	0.9	35
140	The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [18F] fluorodeoxyglucose positron emission tomography scan. <i>Oral Oncology</i> , 2014, 50, 802-808.	0.8	34
141	Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. <i>JAMA Network Open</i> , 2021, 4, e2113205.	2.8	34
142	Gamma knife radiosurgery for recurrent salivary gland malignancies involving the base of skull. <i>Head and Neck</i> , 2003, 25, 210-216.	0.9	33
143	Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1682-1691.	3.3	33
144	High-Dose-Rate Intraoperative Radiation Therapy for Recurrent Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1140-1146.	0.4	32

#	ARTICLE	IF	CITATIONS
145	Current and emerging treatment options for nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2012, 5, 297.	1.0	32
146	Image-based Data Mining to Probe Dosimetric Correlates of Radiation-induced Trismus. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1330-1338.	0.4	32
147	Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. <i>British Journal of Cancer</i> , 2019, 121, 897-903.	2.9	32
148	Multiparametric Imaging of Tumor Hypoxia and Perfusion with ¹⁸ F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1072-1080.	2.8	31
149	Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers. <i>Future Oncology</i> , 2017, 13, 603-613.	1.1	31
150	Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. <i>Cancer</i> , 2020, 126, 1905-1916.	2.0	31
151	Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in <i>ATM</i> . <i>Oncotarget</i> , 2017, 8, 10312-10323.	0.8	31
152	Treatment outcomes for patients with synovial sarcoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 371-373.	1.1	30
153	Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy's local control superior?. <i>Radiology and Oncology</i> , 2014, 48, 56-61.	0.6	30
154	Severe Radiation Dermatitis in Patients With Locally Advanced Head and Neck Cancer Treated With Concurrent Radiation and Cetuximab. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 472-476.	0.6	29
155	High-dose-rate intraoperative brachytherapy and radical surgical resection in the management of recurrent head-and-neck cancer. <i>Brachytherapy</i> , 2013, 12, 228-234.	0.2	29
156	Definitive chemoradiation for primary oral cavity carcinoma: A single institution experience. <i>Oral Oncology</i> , 2015, 51, 709-715.	0.8	29
157	A forward-planned treatment technique using multisegments in the treatment of head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 584-594.	0.4	28
158	Sparing Bilateral Neck Level IB in Oropharyngeal Carcinoma and Xerostomia Outcomes. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 343-347.	0.6	28
159	Impact of elective neck dissection on the outcome of oral squamous cell carcinomas arising in the maxillary alveolus and hard palate. <i>Head and Neck</i> , 2016, 38, E1688-94.	0.9	28
160	Association of Surgical Approach and Margin Status With Oncologic Outcomes Following Gross Total Resection for Sinonasal Melanoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1220.	1.2	27
161	Managing nasopharyngeal carcinoma with intracavitary brachytherapy. <i>Brachytherapy</i> , 2002, 1, 74-82.	0.2	26
162	A study of planning dose constraints for treatment of nasopharyngeal carcinoma using a commercial inverse treatment planning system. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 886-896.	0.4	26

#	ARTICLE	IF	CITATIONS
163	Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab. <i>Head and Neck</i> , 2016, 38, E165-71.	0.9	26
164	Objective assessment of trismus in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT). <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2016, 44, 1408-1413.	0.7	26
165	A magnetic resonance imaging-based approach to quantify radiation-induced normal tissue injuries applied to trismus in head and neck cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 1, 34-40.	1.2	26
166	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. <i>Seminars in Radiation Oncology</i> , 2018, 28, 108-113.	1.0	26
167	A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck. <i>Oral Oncology</i> , 2019, 90, 80-86.	0.8	26
168	Concurrent chemotherapy and radiotherapy for head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 293-302.	1.1	24
169	Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. <i>Cancer</i> , 2012, 118, 3937-3944.	2.0	24
170	Why Target the Globe?: 4-year report (2009-2013) of the Association of Residents in Radiation Oncology Global Health Initiative. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 485-491.	0.4	24
171	Intensity-modulated radiotherapy for head and neck surgeons. <i>Head and Neck</i> , 2016, 38, E2368-73.	0.9	24
172	The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2017, 45, 595-600.	0.7	24
173	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 151, 314-321.	0.3	24
174	The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind" A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. <i>Cancer</i> , 2020, 126, 4092-4104.	2.0	24
175	Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. <i>International Journal of Particle Therapy</i> , 2020, 6, 17-28.	0.9	24
176	Using an onboard kilovoltage imager to measure setup deviation in intensity-modulated radiation therapy for head-and-neck patients. <i>Journal of Applied Clinical Medical Physics</i> , 2007, 8, 28-44.	0.8	23
177	Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 4583-4593.	2.0	23
178	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. <i>Thyroid</i> , 2018, 28, 1180-1189.	2.4	23
179	Reducing the Radiation Therapy Dose Prescription for Elective Treatment Areas in Human Papillomavirus-Associated Oropharyngeal Carcinoma Being Treated With Primary Chemoradiotherapy at Memorial Sloan Kettering Cancer Center. <i>Practical Radiation Oncology</i> , 2019, 9, 98-101.	1.1	23
180	Salvage surgery for recurrent larynx cancer. <i>Head and Neck</i> , 2019, 41, 3906-3915.	0.9	22

#	ARTICLE	IF	CITATIONS
181	Past, present and future of proton therapy for head and neck cancer. <i>Oral Oncology</i> , 2020, 110, 104879.	0.8	22
182	Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 110, 104877.	0.8	22
183	Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: Series of 9 cases and review of the literature. <i>Head and Neck</i> , 2019, 41, 1418-1426.	0.9	21
184	Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 863-868.	0.8	20
185	The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era. <i>Cancer</i> , 2017, 123, 1345-1353.	2.0	20
186	Repeatability of Quantitative Diffusion-Weighted Imaging Metrics in Phantoms, Head-and-Neck and Thyroid Cancers: Preliminary Findings. <i>Tomography</i> , 2019, 5, 15-25.	0.8	20
187	Radiographic osteoradionecrosis of the jaw with intact mucosa: Proposal of clinical guidelines for early identification of this condition. <i>Oral Oncology</i> , 2015, 51, e93-e96.	0.8	19
188	Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, 4.	6.2	19
189	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. <i>Radiotherapy and Oncology</i> , 2020, 153, 97-105.	0.3	19
190	Marginal recurrences after selective targeting with intensity-modulated radiotherapy for oral tongue cancer. <i>Head and Neck</i> , 2012, 34, 900-906.	0.9	18
191	Weekly response assessment of involved lymph nodes to radiotherapy using diffusion-weighted MRI in oropharynx squamous cell carcinoma. <i>Medical Physics</i> , 2015, 43, 137-147.	1.6	18
192	Comparison of mean radiation dose and dosimetric distribution to tooth-bearing regions of the mandible associated with proton beam radiation therapy and intensity-modulated radiation therapy for ipsilateral head and neck tumor. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 122, 566-571.	0.2	18
193	Adjuvant radiation in the TORS era: Is there a benefit to omitting the tumor bed?. <i>Practical Radiation Oncology</i> , 2017, 7, 93-99.	1.1	18
194	Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. <i>Seminars in Radiation Oncology</i> , 2020, 30, 253-261.	1.0	18
195	Treatment Deescalation Strategies for Nasopharyngeal Cancer. <i>JAMA Oncology</i> , 2021, 7, 445.	3.4	18
196	Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1285-93.	0.9	17
197	Sparing of high retropharyngeal nodal basins in patients with unilateral oropharyngeal carcinoma treated with intensity modulated radiation therapy. <i>Practical Radiation Oncology</i> , 2017, 7, 254-259.	1.1	17
198	Advances in nasopharyngeal carcinoma. <i>Current Opinion in Oncology</i> , 2005, 17, 225-230.	1.1	16

#	ARTICLE	IF	CITATIONS
199	Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience. <i>Laryngoscope</i> , 2016, 126, 620-626.	1.1	16
200	Patterns of failure in patients with head and neck carcinoma of unknown primary treated with radiation therapy. <i>Head and Neck</i> , 2016, 38, E426-31.	0.9	16
201	Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times. <i>Journal of Nuclear Medicine</i> , 2016, 57, 334-341.	2.8	16
202	The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 523-531.	0.4	16
203	Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma. <i>Laryngoscope</i> , 2017, 127, 377-382.	1.1	16
204	Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery. <i>Laryngoscope</i> , 2018, 128, 2539-2545.	1.1	16
205	Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach. <i>Head and Neck</i> , 2019, 41, 3551-3563.	0.9	16
206	Hypoxia with 18F-fluoroerythronitroimidazole integrated positron emission tomography and computed tomography (18F-FETNIM PET/CT) in locoregionally advanced head and neck cancer. <i>Medicine (United States)</i> , 2019, 98, e17067.	0.4	16
207	Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. <i>Oral Oncology</i> , 2020, 104, 104641.	0.8	16
208	Association of Number of Dissected Lymph Nodes With Survival in Clinically Node-Negative Oral Cavity Squamous Cell Carcinoma Patients Undergoing Primary Surgery. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1049.	1.2	15
209	Offline Quality Assurance for Intensity Modulated Radiation Therapy Treatment Plans for NRG-HN001 Head and Neck Clinical Trial Using Knowledge-Based Planning. <i>Advances in Radiation Oncology</i> , 2020, 5, 1342-1349.	0.6	15
210	Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. <i>International Journal of Cancer</i> , 2020, 147, 107-115.	2.3	14
211	Computational Modeling of Interstitial Fluid Pressure and Velocity in Head and Neck Cancer Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Feasibility Analysis. <i>Tomography</i> , 2020, 6, 129-138.	0.8	14
212	Squamous cell carcinoma of the tonsil managed by conventional surgery and postoperative radiation. <i>Head and Neck</i> , 2015, 37, 800-807.	0.9	13
213	Safety of contralateral submandibular gland sparing in locally advanced oropharyngeal cancers: A multicenter review. <i>Head and Neck</i> , 2016, 38, 506-511.	0.9	13
214	The head and neck cancer genome in the era of immunotherapy. <i>Oral Oncology</i> , 2021, 112, 105040.	0.8	13
215	Prospectively-validated deep learning model for segmenting swallowing and chewing structures in CT. <i>Physics in Medicine and Biology</i> , 2022, 67, 024001.	1.6	13
216	Impact of concomitant chemoradiation on survival for patients with T1-N1 head and neck cancer. <i>Cancer</i> , 2017, 123, 1555-1565.	2.0	12

#	ARTICLE	IF	CITATIONS
217	Prognostic significance of human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma. <i>Head and Neck</i> , 2020, 42, 2364-2374.	0.9	12
218	Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy?. <i>Oncotarget</i> , 2021, 12, 2223-2226.	0.8	12
219	HPV-associated oropharyngeal cancer de-escalation strategies and trials: Past failures and future promise. <i>Journal of Surgical Oncology</i> , 2021, 124, 962-966.	0.8	12
220	High-dose hypofractionated radiotherapy is effective and safe for tumors in the head-and-neck. <i>Oral Oncology</i> , 2016, 60, 74-80.	0.8	11
221	Organ preservation for patients with anterior mucosal squamous cell carcinoma of the nasal cavity: Rhinectomy-free survival in those refusing surgery. <i>Head and Neck</i> , 2019, 41, 2741-2747.	0.9	11
222	Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy. <i>Head and Neck</i> , 2021, 43, 1056-1062.	0.9	11
223	The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying—the head and neck cancer model. <i>Cancer Causes and Control</i> , 2021, 32, 459-471.	0.8	11
224	A Systematic Review of Proton Therapy for the Management of Nasopharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 119-130.	0.9	11
225	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 319-327.	0.9	11
226	Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis. <i>JCO Oncology Practice</i> , 2022, 18, e780-e785.	1.4	11
227	Case study of the integration of electronic patient-reported outcomes as standard of care in a head and neck oncology practice: Obstacles and opportunities. <i>Cancer</i> , 2021, 127, 359-371.	2.0	10
228	<i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. <i>JCO Precision Oncology</i> , 2021, 5, 1259-1269.	1.5	10
229	Trends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14). <i>International Journal of Particle Therapy</i> , 2019, 5, 1-10.	0.9	10
230	Intensity-modulated radiation therapy for head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 515-521.	1.1	9
231	Impact of Flap Reconstruction on Radiotoxicity After Salvage Surgery and Reirradiation for Recurrent Head and Neck Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 850-857.	0.7	9
232	Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6088-6088.	0.8	9
233	Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot. <i>International Journal of Particle Therapy</i> , 2018, 4, 10-19.	0.9	9
234	Proton beam radiation therapy treatment for head and neck cancer. <i>Precision Radiation Oncology</i> , 2022, 6, 59-68.	0.4	9

#	ARTICLE	IF	CITATIONS
235	Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma. <i>Radiation Oncology</i> , 2013, 8, 173.	1.2	8
236	Cervical nodal level V can safely be omitted in the treatment of locally advanced oropharyngeal squamous cell carcinoma with definitive IMRT. <i>Oral Oncology</i> , 2016, 58, 27-31.	0.8	8
237	Validation and assessment of discordance of the 8th edition AJCC (American Joint Committee on) Tj ETQq1 1 0.784314 rgBT /Overl with surgery and adjuvant radiation at a single institution. <i>Oral Oncology</i> , 2018, 83, 140-146.	0.8	8
238	The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6019-6019.	0.8	8
239	Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration. <i>Current Oncology</i> , 2021, 28, 2409-2419.	0.9	8
240	Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. <i>Cancer Medicine</i> , 2021, 10, 4221-4227.	1.3	8
241	Intensityâ€modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. <i>Cancer</i> , 2021, 127, 4161-4170.	2.0	8
242	A personalized approach using hypoxia resolution to guide curative-intent radiation dose-reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers (OPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6076-6076.	0.8	8
243	Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. <i>Radiotherapy and Oncology</i> , 2022, 167, 179-186.	0.3	8
244	Simplifying intensityâ€modulated radiotherapy plans with fewer beam angles for the treatment of oropharyngeal carcinoma. <i>Journal of Applied Clinical Medical Physics</i> , 2007, 8, 26-36.	0.8	7
245	Correlation of planned dose to area postrema and dorsal vagal complex with clinical symptoms of nausea and vomiting in oropharyngeal cancer (OPC) patients treated with radiation alone using IMRT. <i>Journal of Radiation Oncology</i> , 2013, 2, 407-412.	0.7	7
246	Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers. <i>Head and Neck</i> , 2015, 37, 1633-1641.	0.9	7
247	Patterns of Care in Adjuvant Therapy for Resected Oral Cavity Squamous Cell Cancer in Elderly Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 758-766.	0.4	7
248	Head and neck cancers associated with exposure to the September 11, 2001 World Trade Center terrorist attacks. <i>International Journal of Cancer</i> , 2018, 142, 2485-2490.	2.3	7
249	Feasibility of reirradiation of recurrent sinonasal carcinoma in the periorbital region using hypofractionated imageâ€guided intensityâ€modulated radiation therapy. <i>Head and Neck</i> , 2011, 33, 1372-1378.	0.9	6
250	Longâ€term quality of life in older patients with HPVâ€related oropharyngeal cancer. <i>Head and Neck</i> , 2018, 40, 2321-2328.	0.9	6
251	Comparison of FDG and FMISO uptakes and distributions in head and neck squamous cell cancer tumors. <i>EJNMMI Research</i> , 2021, 11, 38.	1.1	6
252	Counterpoint. <i>Brachytherapy</i> , 2005, 4, 5-7.	0.2	5

#	ARTICLE	IF	CITATIONS
253	Internal and external generalizability of temporal doseâ€“response relationships for xerostomia following IMRT for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 200-206.	0.3	5
254	Predicting radiation dosimetric distribution in different regions of the jaw in patients receiving radiotherapy for squamous cell carcinoma of the tonsil. <i>Head and Neck</i> , 2019, 41, 3604-3611.	0.9	5
255	Patterns of Radiotherapy Use and Outcomes in Head and Neck Softâ€“Tissue Sarcoma in a National Cohort. <i>Laryngoscope</i> , 2020, 130, 120-127.	1.1	5
256	Is It Worth It? Consequences of Definitive Head and Neck Reirradiation. <i>Seminars in Radiation Oncology</i> , 2020, 30, 212-217.	1.0	5
257	Public access to protocols of contemporary cancer randomized clinical trials. <i>Trials</i> , 2021, 22, 418.	0.7	5
258	Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries: Reporting the First Phase of a Prospective International Atomic Energy Agency Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1227-1236.	0.4	5
259	Intensity-Modulated Radiation Therapy in the Treatment of Head and Neck Cancer Involving the Base of the Skull. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S43-S45.	0.4	4
260	Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 234-243.	0.8	4
261	The Importance of Locoregional Therapy in Metastatic Nasopharyngeal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1353.	3.4	4
262	Evaluating compliance with processâ€“related quality metrics and survival in oral cavity squamous cell carcinoma: Multiâ€“institutional oral cavity collaboration study. <i>Head and Neck</i> , 2021, 43, 60-69.	0.9	4
263	Nongaussian Intravoxel Incoherent Motion Diffusion Weighted and Fast Exchange Regime Dynamic Contrast-Enhanced-MRI of Nasopharyngeal Carcinoma: Preliminary Study for Predicting Locoregional Failure. <i>Cancers</i> , 2021, 13, 1128.	1.7	4
264	Cancer of the Larynx. , 2010, , 642-665.		4
265	Outcomes following head and neck cancer surgery among older adults as determined by an electronic geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	4
266	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 799-806.	2.4	4
267	Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 0, , .	3.4	4
268	Distant metastasis is a critical mode of failure for patients with localized major salivary gland tumors treated with surgery and radiation. <i>Journal of Radiation Oncology</i> , 2013, 2, 285-291.	0.7	3
269	Patterns of failure after salvage re-irradiation for recurrent head and neck cancer: implications for field design and consolidation therapy. <i>Journal of Radiation Oncology</i> , 2014, 3, 139-145.	0.7	3
270	Re-Irradiation Therapy for Locally Recurrent Head and Neck Cancer: A National Survey of Practice Patterns. <i>Cancer Investigation</i> , 2017, 35, 393-402.	0.6	3

#	ARTICLE	IF	CITATIONS
271	Optimal mass transport kinetic modeling for head and neck DCE-MRI: Initial analysis. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 2314-2325.	1.9	3
272	Cancer of the Head and Neck. , 2020, , 999-1033.e7.		3
273	Application of Community Detection Algorithm to Investigate the Correlation between Imaging Biomarkers of Tumor Metabolism, Hypoxia, Cellularity, and Perfusion for Precision Radiotherapy in Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2021, 13, 3908.	1.7	3
274	Current considerations for radiotherapy in HPV-associated head and neck cancer. <i>Journal of Surgical Oncology</i> , 2021, 124, 945-951.	0.8	3
275	Influence of Treatment Package Time on outcomes in High-Risk Oral Cavity Carcinoma in patients receiving Adjuvant Radiation and Concurrent Systemic Therapy: A Multi-Institutional Oral Cavity Collaborative study. <i>Oral Oncology</i> , 2022, 126, 105781.	0.8	3
276	In response to Drs. Yao, Dornfeld, and Buatti: the importance of target volume delineation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1639-1640.	0.4	2
277	An Unusual Cause of Isolated Vomiting. <i>Neurology</i> , 2012, 78, 72-73.	1.5	2
278	New Tracers PET in Head and Neck Squamous Cell Carcinoma. <i>PET Clinics</i> , 2012, 7, 431-441.	1.5	2
279	Treatment of maxillary sinus cancer in the modern era: one institution's experience. <i>Journal of Radiation Oncology</i> , 2014, 3, 363-369.	0.7	2
280	Endoscopic Resection Followed by Proton Therapy With Pencil Beam Scanning for Skull Base Tumors. <i>Laryngoscope</i> , 2019, 129, 1313-1317.	1.1	2
281	Postoperative Radiation Therapy to Pathologically Negative Neck Nodal Stations in Patients With Indications for Radiation Therapy at the Primary Site. <i>Practical Radiation Oncology</i> , 2020, 10, 383-385.	1.1	2
282	An imbalance in competing mortality favouring Debio 1143. <i>Lancet Oncology</i> , The, 2020, 21, e502.	5.1	2
283	Beyond reirradiation: Efficacy and safety of three or more courses of radiation for head and neck malignancies. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 30-34.	0.9	2
284	Can the Risk of Dysphagia in Head and Neck Radiation Therapy Be Predicted by an Automated Transit Fluence Monitoring Process During Treatment? A First Comparative Study of Patient Reported Quality of Life and the Fluence-Based Decision Support Metric. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110279.	0.8	2
285	Clinical Review of Proton Therapy in the Treatment of Unilateral Head and Neck Cancers. <i>International Journal of Particle Therapy</i> , 2021, 8, 248-260.	0.9	2
286	Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. <i>Lancet Oncology</i> , The, 2021, 22, e218.	5.1	2
287	Proton Radiation Therapy for Local Control in a Case of Osteosarcoma of the Neck. <i>International Journal of Particle Therapy</i> , 2016, 3, 421-428.	0.9	2
288	Comparison of Objective Measures of Trismus and Salivation With Patient-reported Outcomes Following Treatment for Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 0, , .	1.2	2

#	ARTICLE	IF	CITATIONS
289	Nasopharyngeal Cancer. Medical Radiology, 0, , 17-36.	0.0	1
290	Hypopharyngeal Carcinoma. , 2013, , 29-34.		1
291	Dorsal vagal complex of the brainstem: Conformal avoidance to reduce nausea In Regard to Monroe et al. Practical Radiation Oncology, 2015, 5, e57.	1.1	1
292	Neck spasms: A late sequela of head and neck irradiation. Oral Oncology, 2016, 57, e4-e5.	0.8	1
293	Update of Radiation Techniques Using Photons for Anterior Skull Base Tumors. Advances in Oto-Rhino-Laryngology, 2020, 84, 68-77.	1.6	1
294	Nasopharynx cancer: Induction or adjuvant? That is the question. Cancer, 2020, 126, 3620-3623.	2.0	1
295	Atypical metastasis of nasopharyngeal cancer: noncontiguous spread to the ipsilateral ear. Clinical Imaging, 2021, 72, 70-74.	0.8	1
296	Any day, split halfway: Flexibility in scheduling high-dose cisplatinâ€”A large retrospective review from a high-volume cancer center. International Journal of Cancer, 2021, 149, 139-148.	2.3	1
297	Reproducibility of radiomic features using network analysis and its application in Wasserstein k-means clustering. Journal of Medical Imaging, 2021, 8, 031904.	0.8	1
298	Postoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC).. Journal of Clinical Oncology, 2021, 39, 6060-6060.	0.8	1
299	Hypoxia Imaging for Image-Guided Radiotherapy. , 2010, , 7-18.		1
300	Cancer of the Head and Neck. , 2014, , 1037-1070.e6.		1
301	Primary chondrosarcomas of the larynx treated with proton radiotherapy: A single institutional experience. Cancer Reports, 2022, , e1621.	0.6	1
302	IMRT for Carcinomas of the Nasopharynx. , 2006, , 319-334.		0
303	In Reply to Dr. Nieder. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1653.	0.4	0
304	A Unique Complication Associated with Concurrent Chemoradiation for the Treatment of Locally Advanced Head and Neck Cancer. Clinical Medicine Oncology, 2008, 2, CMO.S407.	0.2	0
305	Hypopharyngeal Carcinoma. Medical Radiology, 2014, , 73-82.	0.0	0
306	Target Delineation of the Neck in Head and Neck Carcinomas. Medical Radiology, 2014, , 147-166.	0.0	0

#	ARTICLE	IF	CITATIONS
307	In Reply to Pareek. International Journal of Radiation Oncology Biology Physics, 2017, 97, 437-438.	0.4	0
308	Salivary Gland Tumors. Practical Guides in Radiation Oncology, 2018, , 153-163.	0.0	0
309	Tumors of the Nasopharynx. Practical Guides in Radiation Oncology, 2018, , 107-116.	0.0	0
310	Oral Cavity Tumors. Practical Guides in Radiation Oncology, 2018, , 117-130.	0.0	0
311	To Shy Away From Chemotherapy Is to Compromise. International Journal of Radiation Oncology Biology Physics, 2020, 107, 616-617.	0.4	0
312	High-Dose Chemoradiation Irrespective of Age. International Journal of Radiation Oncology Biology Physics, 2021, 111, 11-12.	0.4	0
313	Intensity-Modulated Radiation Therapy for Nasopharyngeal Cancer. Practical Guides in Radiation Oncology, 2021, , 71-81.	0.0	0
314	Patient selection for immunotherapy in head and neck cancer – Authors' reply. Lancet Oncology, The, 2021, 22, e291-e292.	5.1	0
315	The effect of short radiation treatment breaks on chemo–radiotherapy for oropharyngeal cancers. Head and Neck, 2021, 43, 3796-3809.	0.9	0
316	Cancer of the Hypopharynx. , 2010, , 613-641.		0
317	Cancer of the Nasopharynx. , 2010, , 523-545.		0
318	Intensity-Modulated Radiation Therapy for Head and Neck Cancer. , 2011, , 267-279.		0
319	Nasopharyngeal Cancer. , 2015, , 153-169.		0
320	Intensity-Modulated Radiation Therapy for Head and Neck Cancer. , 2016, , 301-315.		0
321	Recurrent/Metastatic Head and Neck Cancer: When and How to Irradiate. , 2017, , 209-219.		0
322	Well-Differentiated Thyroid Cancer: Who Should Get Postoperative Radiation?. Annals of Surgical Oncology, 2022, , .	0.7	0
323	Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy. International Journal of Particle Therapy, 2022, 9, 20-30.	0.9	0